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Abstract
Glycoproteinoses belong to the lysosomal storage disorders group. The common feature of these diseases is the deficiency
of a lysosomal protein that is part of glycan catabolism. Most of the lysosomal enzymes involved in the hydrolysis of
glycoprotein carbohydrate chains are exo-glycosidases, which stepwise remove terminal monosaccharides. Thus, the
deficiency of a single enzyme causes the blockage of the entire pathway and induces a storage of incompletely degraded
substances inside the lysosome. Different mutations may be observed in a single disease and in all cases account for the non-
expression of lysosomal glycosidase activity. Different clinical phenotypes generally characterize a specific disorder, which
rather must be described as a continuum in severity, suggesting that other biochemical or environmental factors influence the
course of the disease. This review provides details on clinical features, genotype-phenotype correlations, enzymology and
biochemical storage of four human glycoprotein lysosomal storage disorders, respectively K- and L-mannosidosis, fucosidosis
and K-N-acetylgalactosaminidase deficiency. Moreover, several animal disorders of glycoprotein metabolism have been
found and constitute valuable models for the understanding of their human counterparts. ß 1999 Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
‘Glycoproteinoses’ constitute a peculiar group of
lysosomal storage disorders, in which the common
feature is the genetic abnormality of a lysosomal
protein involved in the catabolic pathway of glyco-
proteins. The de¢cient protein may be a glycosidase,
a cofactor or a lysosomal membrane carrier which
delivers catabolic products to the cytosol. Most lyso-
somal glycosidases are exo-hydrolases that degrade
step-wise the glycan at the nonreducing end (Fig. 1)
[1,2]. The lack of a single enzyme leads to the com-
plete blockage of the catabolic chain and results in
the accumulation of undegraded oligosaccharides in
lysosomes. An elevated urinary excretion of carbohy-
drate material is also observed in patients. In the
four diseases discussed in this chapter, a¡ected indi-
viduals have very low or undetectable amount of the
enzyme activity inside the lysosome and in most
cases absence of cross-reacting material. This indi-
cates that in these diseases the mutations result in
an unexpressed protein. Despite this fact there is a
continuum of clinical phenotypes, indicating that
other factors in£uence the course of the disease. De-
lineation of each of these distinct diseases on the




The main clinical symptoms are progressive mental
retardation, immunode¢ciency, and impaired hearing
and Hurler-like skeletal changes [3] with typical ver-
tebral bodies, which are prominently involved with
ovoid con¢gurations. Other ¢ndings are lens opac-
ities, muscular hypotonia, macroglossia and progna-
theism. The clinical severity of K-mannosidosis
ranges in a continuum from mildly a¡ected to se-
verely a¡ected patients, nevertheless the disease is
classically divided into two phenotypes: a severe in-
fantile phenotype referred to as type I and a milder
juvenile-adult phenotype referred to as type II [4].
The di¡erence in the clinical course of the disease
may be in part due to external factors not relevant to
the primary genetic defect. Berg et al. [5] indicate
that most patients do not show any enzyme activity,
although they are mildly a¡ected. This suggests that
other genetic or environmental factors in£uence the
clinical phenotype. Particularly it has been advanced
that the storage of oligomannosides in serum of the
patients may interfere with molecules of the immune
system leading to the observed immunode¢ciency
among mannosidosis patients [6,7].
Histological investigations demonstrate the pres-
ence of vacuolated lymphocytes, hepatocytes and
Kup¡er cells [8].
2.1.2. Enzymatic defects
Multiple forms of K-mannosidases (EC 3.2.1.24)
with di¡erent subcellular locations have been de-
scribed [9]. Lysosomal K-mannosidase (LAMAN)
[10] is a¡ected in mannosidosis. This enzyme presents
a broad substrate speci¢city, hydrolyzing K(1^2),
K(1^3) and K(1^6) mannosyl linkages found in
high-mannose and hybrid type glycans [11^14].
This enzyme is distinguished from other cellular K-
mannosidase activities by a combination of a low pH
optimum (pH 4.5), Zn2 dependence, a broad natu-
ral substrate speci¢city, an activity towards the arti-
¢cial substrate p-nitrophenyl-K-mannoside and an in-
hibition by swainsonine [11^15].
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The enzyme belongs to the class II K-mannosidases
and presents sequence similarity to the Golgi K-man-
nosidase II, Golgi mannosidase IIx, mannosidase
from epididymis [16] and the cytosolic/endoplasmic
reticulum K-mannosidase [15]. According to the clas-
si¢cation of Henrissat and Bairoch [17] the enzyme
belongs to family 38 of the glycosylhydrolases. The
lysosomal K-mannosidase has been puri¢ed from a
number of mammalian sources [13,18^21] and is gen-
erally isolated as a complex consisting of 2 to 10
di¡erent peptides. Biosynthetic studies in human ¢-
broblasts have demonstrated that the enzyme is syn-
thesized as a 110 kDa precursor and is proteolyti-
cally cleaved into fragments of 40^46 kDa and 63^
67 kDa upon transport to lysosomes [22].
Within a single tissue, acidic K-mannosidase occurs
as isoenzymes: two isoenzymes designated A and B
have been isolated by ion-exchange chromatography
and di¡er only in their isoelectric point according to
their degree of sialylation and/or phosphorylation of
the mannose residues [18].
LAMAN has been cloned by several groups [23^
26]. LAMAN was demonstrated to be synthesized as
a single chain precursor, which is further processed
into three peptides with molecular masses of 70 kDa,
42 kDa and 13/15 kDa. The 13/15 kDa fragment was
not detected in the previously mentioned study [22]
by using metabolic labeling in human ¢broblasts.
Further speci¢c processing of the 70 kDa subunit
results in a total of ¢ve di¡erent peptides a (39
kDa), b (8/10 kDa), c (20/22 kDa), d (42 kDa) and
e (13/15 kDa) [26].
In addition to the ‘broad spectrum’ acid K-man-
nosidases, a ‘core speci¢c’ K-mannosidase, hydrolyz-
Fig. 1. The bi-directional catabolic pathway for N-acetyllactosaminic glycoproteins.
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ing the Man(K1^6) linkage of the common triman-
nosyl core, has also been characterized [27^29].
2.1.3. The mutations
The gene encoding lysosomal K-mannosidase has
been localized close to the centromere of chromo-
some 19 (19 p 13.2^q 12) by analysis of human ro-
dent somatic cell hybrids for K-mannosidase activity
[30,31] and by polymerase chain reaction (PCR)
screening of a human rodent cell hybrid mapping
panel DNA [24]. The genomic structure of the hu-
man lysosomal K-mannosidase gene (MAN B) has
Fig. 2. Structures of oligosaccharides accumulated in urine from human K-mannosidosis.
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been established [32]. The gene spans 21.5 kb and
contains 24 exons. Several mutations, including splic-
ing, missense or nonsense mutations have been char-
acterized among patients [26,32,33]. No direct corre-
lation between the types of mutations and the clinical
manifestations are evident. The most commonly ob-
served mutation causes an amino-acid substitution
(R750 W) and accounts for 21% of the disease alleles
in European patients.
2.1.4. The storage material
Mannosidosis patients accumulate oligomanno-
sides in tissues and urine [34^41] (Fig. 2). These sub-
strates originate from the incomplete catabolism of
high-mannose and hybrid-type glycans. High-man-
nose type oligomannosides are normally poorly
present on mature glycoproteins but are found on
newly synthesized glycoproteins undergoing the gly-
can biosynthetic trimming inside rough endoplasmic
reticulum. They also occur on polyprenic lipid inter-
mediates (dolichol-oligosaccharides). One possible
origin of high-mannose oligosaccharides undergoing
the lysosomal catabolism by K-mannosidase is in the
so-called ‘quality control’ of newly biosynthesized
glycoproteins [42^44].
It is now well established that misfolded glycopro-
teins are retained inside the ER by the two lectins
calnexin and calreticulin [45,46] and are ¢nally catab-
olized both in ER and cytosol [47,48]. The generated
oligosaccharides are further transferred to lysosomes
[49,50]. Another origin for oligosaccharides is in the
catabolism of dolichol-phospho-oligosaccharides due
to the hydrolytic activity of the oligosaccharidyl-
transferase enzyme [44].
Several observations may be deduced from the pri-
mary structures of stored oligosaccharides. (1) All
the oligosaccharides are terminated at the reducing
end by a single GlcNAc residue, due to the activity
of the lysosomal chitobiase [51,52]. (2) The major
compound is the trisaccharide Man(K1^3)Man(L1^
4)GlcNAc; the Man(K1^6) counterpart is never
found as well as the trimannose structure Man(K1^
3)[Man(K1^6)]Man(L1^4)GlcNAc which would be
expected as the major stored oligosaccharide. These
observations could be related to the presence of re-
sidual K1^6 mannosidase activity [27,29]. (3) A num-
ber of oligosaccharides possess ‘linear’ structures
with K1^2 linked mannose on one branch. Such oli-
gosaccharides may originate from the previous cyto-
solic catabolism by the soluble K-mannosidase activ-
ity [53^55]. Indeed, a complementary action of
cytosolic and lysosomal K-mannosidases has been
demonstrated [53].
2.1.5. Animal mannosidosis
K-Mannosidosis is also known to occur in cattle
[56] and in cats [57]. First described in Angus cattle
in New Zealand and Australia, the disease was a
subsequently diagnosed in Angus cattle in Europe
and the United States [58,59] and in Galloway cattle
in Australia [60]. The majority of a¡ected Angus
calves fail to survive the immediate postnatal period,
but those that do, show severe, progressive neuro-
logical disease characterized by tremors of the head
and ataxia.
Bovine lysosomal K-mannosidase as its human
counterpart consists of three glycopeptides of respec-
tively 67 kDa, 38 kDa and 13/15 kDa [61]. The 67
Fig. 2. (continued)
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kDa fragment is further processed into three peptides
of 35/38 kDa, 22 kDa and 11/13 kDa that are joined
by disul¢de bridges. The enzyme has been cloned and
two missense mutations were established in Angus
and Galloway cattle, respectively. The mutation in
Angus (961 T to C transition) results in a reduced
expression of LAMAN polypeptide, yet the residual
activity has a Km and thermal stability similar to that
of the normal enzyme. The mutation in Galloway
(662 G to A transition), however, causes a change
of the temperature stability, indicating a change in
protein conformation. Feline K-mannosidase has also
been recently cloned [62]. The enzyme consists of
three polypeptides of 72, 41 and 12 kDa joined by
noncovalent forces. Mutation in Persian cats causes a
4 bp deletion, with disappearance of the enzyme ac-
tivity in tissues.
2.1.6. Storage material
As in human mannosidosis, oligomannosides are
stored in tissues and excreted in the urine of a¡ected
animals [63^67]. Their structures di¡er from those
found in humans in two respects. (1) Most of the
oligosaccharides possess the di-N,NP-acetyl-chito-
biose sequence at their reducing end. This result
agrees with the absence of lysosomal chitobiase in
these species [68,69]. (2) Unlike human mannosido-
sis, the major oligosaccharide consists of Man(K1^6)-
Man(L1^4)GlcNAc(L1^4)GlcNAc [64]. This observa-
tion may be related to the absence of the residual
K1^6-mannosidase activity present in humans. In
particular, it has been speculated that this activity
is directly associated to the lysosomal chitobiase
[11]. As a result, the catabolic pathway of oligoman-
nosides appears to be species-speci¢c.
2.2. L-Mannosidosis
2.2.1. Clinical aspects
Genetic disorders associated with L-mannosidases
de¢ciency have been described in Nubian goats [70^
72], Salers cattle [73], and humans [74^83].
Ruminants a¡ected by the disease present severe
neurological de¢ciencies associated with myelin ab-
normalities [84^86] leading to a rapid neonatal death,
as well as facial dysmorphism contractures and hy-
perextension of the limb joints and deafness.
Unlike the severe clinical manifestations of the dis-
ease in ruminants, the human disease phenotype is
generally milder, and heterogeneous in its clinical
spectrum, with a wide range of symptoms and age
of onset [83]. It is still di⁄cult to distinguish a con-
sistent pattern of clinical manifestation for L-manno-
sidosis. The disease is associated with a range of
neurological involvements including various degrees
of mental retardation except for two cases [77,78],
hearing loss and speech impairment [74,76,79,81], hy-
potonia [76,78,82], epilepsy [77] and peripheral neu-
ropathy [79]. There is no evidence for severe dysmye-
lination as observed in the animal disease. Other
clinical symptoms are angiokeratoma [74,80], facial
dysmorphism [75,79,83] and skeletal abnormalities
[75,79].
2.2.2. The enzymatic defect
The lysosomal enzyme L-mannosidase (EC
3.2.1.25) cleaves the L-linked mannose residue
present in all types of N-glycosylprotein glycans. L-
Mannosidase has been partially puri¢ed and incom-
pletely characterized from several mammalian sour-
ces [87^91].
The goat kidney lysosomal L-mannosidase has
been puri¢ed by immunoa⁄nity [91] and consists of
two peptides of 90 and 100 kDa, respectively, corre-
sponding to two related forms of the enzyme. The
two peptides of 90 and 100 kDa di¡er both in N-
glycans and proteolytic processing as found by Mr
estimation after PNGase F treatment (86^91 kDa)
[91]. The bovine enzyme [89] was shown to have
three molecular masses between 90 and 110 kDa.
From these papers one could assume that the mam-
malian L-mannosidases are synthesized as one chain
precursor of about 110 kDa and subjected to limited
N-terminal and C-terminal proteolysis in a species-
speci¢c way. Human, goat and bovine L-mannosi-
dases have been cloned and mutations leading to
the human and goat diseases identi¢ed [92^94]. The
caprine cDNA codes for an 879 amino acid peptide;
a¡ected animals present a single base deletion in the
cDNA, resulting in a shift in the reading frame and a
premature termination of translation yielding a de-
duced peptide of 481 amino acids. The human gene
was localized on chromosome 4q22^25. Mutation
analysis in two siblings di¡erently a¡ected with L-
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mannosidosis demonstrated a homozygous ACG
transition, resulting in two abnormally spliced mu-
tant mRNA species in both siblings [93].
2.2.3. The storage material
Di¡erent oligosaccharides consisting of the disac-
charide Man(L1^4)GlcNAc and other more complex
oligosaccharides [95^101] (Fig. 3) accumulate in the
tissues and urine of a¡ected animals.
The sialylated trisaccharide NeuAc(K2^6)Man-
(L1^4)GlcNAc isolated from human L-mannosidosis
urine probably results from an abnormal sialylation
of the Man(L1^4)GlcNAc precursor [102,103].
3. Fucosidosis
Fucosidosis is an autosomal recessive lysosomal
storage disease caused by defective lysosomal K-L-
fucosidase with accumulation of fucosylated glyco-
conjugates in tissues. By 1991, only 77 patients
with fucosidosis had been described [104].
3.1. Clinical aspects
The clinical features of fucosidosis are progressive
mental retardation and neurological deterioration,
coarse facies, growth retardation, recurrent infec-
tions, dysostosis multiplex, angiokeratoma. Tradi-
tionally, two clinical subtypes (type 1 and 2) are gen-
erally di¡erentiated [104,105]. Type 1 is described as
the severe infantile form with a general deterioration
of the neurological functions at the age of 1 or 2
years. Type 2 is a milder form; symptoms appear
progressively and the patients survive into the second
or third decade of life. It has been suggested that
these two clinical subtypes were genetically deter-
mined by di¡erent mutations. In an excellent review
of 77 cases, Willems and colleagues demonstrate a
wide range of severity of the disease existing in the
same family, moreover that type 1 and 2 represent
two extremes of a continuous clinical spectrum. The
cause of the clinical variability of fucosidosis is not
understood and suggests the importance of other ge-
netic or nongenetic factors.
3.2. Enzymatic defect
K-L-Fucosidase (EC 3.2.1.51) is involved in the
cleavage of terminal fucose linked K1^2 to a galac-
tose residue and of fucose linked K1^3, K1^4 or K1^6
to an N-acetylglucosamine residue on glycoproteins
and glycolipids. [106]. The enzyme is a homotetramer
composed of subunits of approximately 50 to 60
kDa: these molecular mass di¡erences are due to
variation in N-glycosylation and proteolytic process-
ing [107].
The K-L-fucosidase gene (FUCA 1) has been local-
ized to chromosome 1p34 [108,109] and contains
eight exons spanning 23 kb [110]. cDNA encodes
an unprocessed protein of 461 amino acids, including
22 amino acids of the signal peptide and 439 amino
acids encoding the mature protein [111,112].
A pseudogene was found on chromosome 2 and is
80% identical to K-L-fucosidase cDNA: it contains
no intron and has no open reading frame [110]. A
locus on chromosome 6 (FUCA2) linked to the plas-
minogen locus in£uences plasma fucosidase activity
but not leukocyte fucosidase activity. This gene is
not involved in fucosidosis [113].
More than 20 mutations in the FUCA 1 gene have
been identi¢ed leading either to fucosidosis or to a
polymorphism [114,115]. The most frequent muta-
tion is a C to T transition that results in the gener-
ation of an ‘in frame’ stop codon (CAACTAA at
codon 422)(Q422X) that is found in six di¡erent fam-
ilies in Italy and in families in France, Cuba and
Canada [116]. The other mutations result in prema-
ture stop defect, frameshift and alteration of splicing.
Amino acid substitutions occurring in conserved re-
gions result in a severe form of the disease (G60D,
S63L, N379Y) [115,117]. Recently a mutation L405R
was described in a 46-year-old patient with a less
severe clinical phenotype [118]. Amino acid substitu-
tion Q281R is responsible for the polymorphism de-
tected by isoelectric focusing (Fu1/Fu2) [119]. The
observed clinical variability is therefore not due to
Fig. 3. Structures of oligosaccharides accumulated in urine and
tissues from goat and human L-mannosidosis. (A) Human and
goat; (B,D) goat; (C) human.
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the nature of fucosidosis mutation, but to secondary
unknown factors [114,116].
K-L-Fucosidase enzyme activity in fucosidosis pa-
tients is nearly absent and CRIM (cross reacting im-
munological material) is below 6% of the normal
mean [104].
3.3. Storage material
Fucosidosis patients accumulate in tissues and
urine fucosylated glycoconjugates originating from
incomplete catabolism of N- and O-glycosylproteins,
glycolipids and proteoglycans. There is a major ac-
cumulation of glycolipids expressing blood group
antigens (H, X) in liver. Oligosaccharides and glyco-
asparagines are stored in tissues and abnormally ex-
creted in urine [120^125] (Fig. 4).
In the urine of patients with fucosidosis a large
amount of glycopeptides is present. These glycopep-
tides are characterized by the presence of an K1^6-
Fig. 4. Structures of the major glycoasparagines and oligosaccharides from fucosidosis urine.
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linked fucose to the chitobiose core. The major gly-
copeptide, a glycoasparagine Fuc(K1^6)GlcNAcL1-
Asn present in urine corresponds to the linkage re-
gion of the oligosaccharide [126]. The large amount
of glycopeptides excreted is unique to fucosidosis and
can be explained by the steric inhibition of the gly-
cosylasparaginase by the fucose residue; the nonfu-
cosylated glycoasparagines are normally processed
and only fucosylated glycoasparagine and oligosac-
charides without K1^6 linked fucose residue accumu-
late [2,28,127].
Analysis of urinary glycoconjugates from two pa-
tients with di¡erent phenotypes of fucosidosis, type I
(acute) and type II (chronic) indicated an increased
amount of FucK1^6 GlcNAcL1-Asn glycoasparagine
in the type II patient as compared to the type I
patient. On the other hand an hexasaccharide pos-
sessing a Lewis X determinant at the periphery of the
oligosaccharide was present in much greater quanti-
ties in urines of the type I patient [125]. An inverse
relationship between terminal oligosaccharide chain
fucosylation and core K1^6 fucosylation has been
shown in the case of human blood group H fucosyl-
transferase (Fuc-TI) [128]. If a similar inhibition is
found with K1^3 fucosylation, it would explain the
urinary phenotypes observed and furthermore a cor-
relation between the expression of the di¡erent fuco-
syltransferases (Fuc-TI, to FucTVII) [129] and the
clinical phenotypes (type I and II) or a relationship
between the nature of the stored lysosomal material
and the severity of the disease could be made.
3.4. Treatment
Correction of the enzymatic de¢ciency by alloge-
neic bone marrow transplantation has been ¢rst ex-
perienced on an animal model [130] and more re-
cently an 8-month-old boy has been transplanted
with an amelioration of the clinical signs [131]. In
the future, gene therapy may be an alternative treat-
ment [132,133].
4. K-N-Acetylgalactosaminidase de¢ciency (Schindler
disease and Kanzaki diseases)
The de¢ciency of lysosomal K-N-acetylgalactos-
aminidase (K-NAGA) was ¢rst reported in Germany
[134]. Only eight patients have been described [135],
and the clinical heterogeneity and genetic and bio-
Fig. 4. (continued)
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chemical data suggest that the phenotypic variation
of this disease is in£uenced by numerous factors oth-
er than K-NAGA.
4.1. Clinical aspects
Two clinical subtypes have been described.
Type I K-NAGA de¢ciency is an infantile-onset
form, designated as Schindler disease, characterized
by a neurodegenerative syndrome resembling Seitel-
berger disease (infantile neuroaxonal dystrophy)
[136]. The ¢rst two patients described in Germany
had a normal development until the age of one and
thereafter a rapid regression of their previously ac-
quired mental skills took place. Other neurological
signs observed are myoclonic seizures, cortical blind-
ness, spasticity and decorticate posturing. Contrary
to other lysosomal storage diseases, no visceral ab-
normalities are observed [137]. This neuropathology
characterized by the presence of ‘spheroids’ in termi-
nal axons, classi¢ed this disease as a neuroaxonal
dystrophy [138].
Type II is an adult-onset disease with mild pheno-
typic expression and was ¢rst described in a 46-year-
old Japanese woman with angiokeratoma corporis
di¡usum, mild intellectual impairment, and periph-
eral neuroaxonal degeneration [139]. Two other adult
patients with a very similar phenotype were described
in Spain [140].
Another intermediate phenotype was described in
two Dutch children [141].
As previously described for L-mannosidosis, an ex-
treme diversity of the clinical phenotypes is observed
among patients [135].
4.2. Enzymatic defect
K-N-acetylgalactosaminidase (EC 3.2.1.49) is a ly-
sosomal enzyme, initially thought to be an isoenzyme
of K-galactosidase and thereafter called also K-galac-
tosidase B. The two enzymes have similar physico-
chemical properties, a subunit molecular mass of 49
kDa, homodimeric structure and a similar amino
acid composition (reviewed in [8]).
K-N-Acetylgalactosaminidase has an acidic opti-
mal pH (pH 4.6) and hydrolyzes aryl-K-N-acetylga-
lactosaminides and aryl-K-galactosides and is inhib-
ited by the product of hydrolysis, N-acetylgalac-
tosamine [142]. K-N-Acetylgalactosaminidase is
known to act on N-acetylgalactosamine linked to
serine or threonine as an exoglycosidase.
The K-N-acetylgalactosaminidase gene has been lo-
calized to chromosome 22 [143] and contains nine
exons spanning 14 kb [144]. cDNA encodes an un-
processed protein of 411 amino acids including the
mature protein of 394 amino acids [142]. There is a
high degree of amino acid sequence similarity be-
tween K-galactosidase (K-galactosidase A) and K-N-
acetylgalactosaminidase (K-galactosidase B), suggest-
ing they have evolved from a common ancestral gene
[144].
Four di¡erent mutations have been described
[135]. The German type I probands had a G to A
transition at nucleotide 973 that resulted in a substi-
tution of a glutamic acid to a lysine residue (E325K)
[145]. The type II Japanese patient had a substitution
of an arginine to a tryptophan residue (R329W)
[146]. The Dutch patients reported by de Jong [141]
showed two mutations, the previously described
E325K and a new one, S160C [135]. Finally, the
Spanish patients are homozygous for the nonsense
mutation E193X [135]. Keulemans and colleagues
demonstrated the absence in all the di¡erent patients
of immunologically detectable K-N-acetylgalactos-
aminidase; the activity of the enzyme was barely
detectable and only one Dutch patient had a residual
activity of 4% [135]. Finally, no correlation can be
made at the moment between the severity of the dis-
ease and the mutation of the enzyme suggesting that
K-N-acetylgalactosaminidase de¢ciency is a multifac-
torial disease. It should be pointed out that K-N-ace-
tylgalactosamine occurs in the blood group A sub-
stance and thus the blood group status of the patient
may in£uence the degree of severity of the disease.
Some mutations may also a¡ect the enzyme folding
in the ER and impair their arrival in the lysosome.
4.3. Storage material
K-Linked N-acetylgalactosamine occurs (i) at the
termini of glycoconjugates as part of the blood group
A determinant (GalNAcK1^3(FucK1^2)Gal) in gly-
colipids or in O- and N-linked oligosaccharides of
glycoproteins or as part of Forssman antigen on gly-
colipids: (GalNAcK1^3GalNAcL1^3GalK1^4GalL1^
4GlcL1^1PCer); (ii) at the reducing end of O-linked
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oligosaccharide. One would expect that the com-
pound accumulating in this lysosomal disease would
always possess a terminal GalNAc residue. The
blood group A German patient described by Schind-
ler and colleagues excreted in the urine the blood
group A trisaccharide and glycopeptides possessing
the common element GalNAcK1-O-Ser/Thr, substi-
tuted or not. Remarkably, most of these glycopep-
tides possess galactose and sialic acid residues at-
tached to the core N-acetylgalactosamine residue
and are similar to those excreted in sialidosis and
galactosialidosis patients [136]. This might indicate
that (i) the K-N-acetylgalactosaminidase is part of
an enzymatic protein complex with sialidase, galac-
tosidase and the protective protein and, as a con-
sequence of the mutation of the K-N-acetylgalactos-
aminidase, the protein complex structure is less
e⁄cient in the degradation of O-linked sialylated
glycopeptides; (ii) there is a phenomenon of trans-
glycosylation on the primarily accumulated Gal-
NAcK1CO-Ser/Thr as observed in other lysosomal
diseases [2,147].
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